Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Institut Curie Strengthens Pioneering Research with Innovative Biobanking Technology

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
TTP Labtech’s arktic system chosen for technical excellence and provision of long term sample security.

The new phase of expansion for Institut Curie’s Paris-based biobank required a solution for advanced patient sample monitoring, as well as efficient sample storage and preparation across numerous tissue formats, including tumour, RNA, DNA, protein and blood. As part of this upgrade Institut Curie announced today an investment in arktic®, a flexible, modular -80°C sample storage system from a leading technology provider, TTP Labtech.

This platform has been selected by the Institut Curie as part of its longer term strategy encompassing biobank expansion, in particular in the framework of the Equipex initiative conducted by French government of which Institut Curie has been a major laureate. TTP Labtech’s arktic promises to provide a valuable resource for the outstanding oncology research, patient diagnostics and pioneering treatment regimens that the Institut Curie is renowned for. The installation of which is a necessary step to ensure the security of the institute’s invaluable and growing sample repository, and will ensure that issues around sample integrity and availability will not be factors limiting the quality, impact and insight of future research.

Dr. Xavier Sastre-Garau, Director of Pathology at the Institut Curie commented: “We have been impressed with the level of scientific innovation and engineering know-how provided by the TTP Labtech team. We required a future-proofed system that had the flexibility to grow as our biobank expanded, could store a range of different sample types and volumes and could facilitate better sample management and tracking. TTP Labtech’s arktic has provided a solution to these requirements. The small footprint of the arktic also greatly aids our facility design and set-up and allows us to make the best use of our space.” 

James Craven, Commercial Head of Sample Management at TTP Labtech commented, “We are honoured to have been chosen by Institut Curie at this very critical phase of expansion.  The Institut curie provides invaluable research in the fight against Cancer”. TTP Labtech’s arktic storage modules have no moving parts within the cold zone. Instead, internal sample transport relies on its proprietary pneumatic technology, greatly improving the efficiency and mechanical reliability of the system.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TTP Labtech Revenues up 43%
The company has reported an impressive 43% increase in revenues and an associated increase in profits over 2013.
Monday, June 23, 2014
TTP LabTech to present “Genome-Wide siRNAi Screening” tutorial at RNAi Europe
TTP LabTech will be presenting a tutorial on ‘Genome-Wide siRNAi Screening Using the Acumen eX3 – A Customer Perspective from Cancer Research UK’ on Thursday 17th September at the RNAi Europe 2009 conference.
Thursday, August 20, 2009
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!